NCT03984097 2026-03-10
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Active not recruiting
Clinical Trials
7 trialsNCT04328662 2026-03-04
A Study of Ninlaro in Real World Clinical Practice in China
Takeda
Completed
NCT04155749 2026-02-11
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Active not recruiting
NCT05651932 2026-02-10
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT06152575 2026-02-03
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT07354555 2026-01-21
MMExFFPE
BIWAKO
Not yet recruiting
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed